21256-18-8
Chemical Structure
Oxaprozin
Synonym(s): Oxaprozinum; Wy21743
- No. CAS: 21256-18-8
- Formula:C18H15NO3
- Molecular Weight:293.32
IUPAC Name: 3-(4,5-diphenyloxazol-2-yl)propanoic acid
InChIKey: OFPXSFXSNFPTHF-UHFFFAOYSA-N
SMILES: O=C(O)CCC1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)O1
Biological Activity: Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties[1][2].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Oxaprozin | 99.94% | Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oxaprozin (Standard) | ≥98% | Oxaprozin (Standard) is the analytical standard of Oxaprozin. This product is intended for research and analytical applications. Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oxaprozin-d5 | Oxaprozin-d5 is deuterium labeled Oxaprozin. Oxaprozin is an inhibitor of both COX-1 and COX-2 with IC50s of 2.2 μM and 36 μM for human platelet COX-1 and IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oxaprozin-d10 | Oxaprozin-d10 (Oxaprozinum-d10; Wy21743-d10) is the deuterium labeled Oxaprozin (HY-B0808). Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oxaprozin-d4 | 99.08% | Oxaprozin-d4 is the deuterium labeled Oxaprozin, which is a non-steroidal anti-inflammatory agent (NSAID). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ottonello L, et al. Delayed apoptosis of human monocytes exposed to immune complexes is reversed byoxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157(2):294-306. [Content Brief]
- [2]. Montecucco F, et al. Oxaprozin-induced apoptosis on CD40 ligand-treated human primary monocytes is associated with the modulation of defined intracellular pathways. J Biomed Biotechnol. 2009;2009:478785. [Content Brief]
